Dr. Geoffrey Sklar On Immunotherapy Advancements in Bladder Cancer

Geoffrey Sklar, MD
Published: Friday, Nov 04, 2016


Dr. Geoffrey Sklar, Chief Medical Officer, Chesapeake Urology Associates, spoke with OncLive about some of the exciting advancements in bladder cancer during the LUGPA Annual Meeting.
 
The PD-L1 inhibitor drugs that have been approved for advanced bladder cancer are currently an exciting topic. A big question that remains is whether these can be effective in early disease as a neoadjuvant treatment, Sklar says.
 
Other areas, such as high-grade non-invasive bladder cancers, are currently an enigma, as there are not many treatments available. The goal is to see if there is a place for these diseases in that treatment paradigm, Sklar says.
 

Dr. Geoffrey Sklar, Chief Medical Officer, Chesapeake Urology Associates, spoke with OncLive about some of the exciting advancements in bladder cancer during the LUGPA Annual Meeting.
 
The PD-L1 inhibitor drugs that have been approved for advanced bladder cancer are currently an exciting topic. A big question that remains is whether these can be effective in early disease as a neoadjuvant treatment, Sklar says.
 
Other areas, such as high-grade non-invasive bladder cancers, are currently an enigma, as there are not many treatments available. The goal is to see if there is a place for these diseases in that treatment paradigm, Sklar says.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x